Pharmagreen Biotech Inc 10-Q/A, filed Feb 23, 2021
Pharmagreen Biotech Inc. (PHBI)
About this 10-Q/A
Pharmagreen Biotech Inc filed this 10-Q/A on February 23, 2021, covering the quarter ended December 31, 2020.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2020
or
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
000-56090
Commission File Number
PHARMAGREEN BIOTECH INC.
(Exact name of registrant as specified in its charter)
Nevada 98-0491567
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
2987 Blackbear Court, Coquitlam, British Columbia V3E 3A2
(Address of principal executive offices)(Zip Code)
702-803-9404
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
(X)Yes (_) No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
(_)Yes (_) No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer | ¨ | Non-accelerated filer | ¨ |
Accelerated filer | ¨ | Smaller reporting company | x |
|
| Emerging Growth | x |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act (X)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
( ) Yes (X) No
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.
( ) Yes ( ) No
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of February 19, 2021, we had 314,261,669 shares of common stock issued and outstanding.
Explanatory Note: The purpose of this Amendment No. 1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020, filed with the Securities and Exchange Commission on February 22, 2021 (the “Form 10-Q”), is to include financial statements in XBRL format.
This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date and does not modify or update the disclosures made in the original Form 10-Q except as noted above.
The following documents are filed as a part of this report or are incorporated by reference to previous filings, if so indicated:
Exhibit |
| Description |
|
|
|
|
|
|
31.1 (1) |
| Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934* |
|
|
|
31.2 (1) |
| Certification of Chief Executive Officer Pursuant to Rule 13a–14(a) or 15d-14(a) of the Securities Exchange Act of 1934** |
|
|
|
32.1 (1) |
| Certification of Chief Executive Officer under Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
|
|
|
32.2 (1) |
| Certification of Principal Financial Officer under Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002** |
|
|
|
101.INS (2) |
| XBRL Instance File |
|
|
|
101.SCH (2) |
| XBRL Taxonomy Schema Linkbase Document |
|
|
|
101.CAL (2) |
| XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
|
101.DEF (2) |
| XBRL Taxonomy Extension Definition Linkbase Document |
|
|
|
101.LAB (2) |
| XBRL Taxonomy Extension Label Linkbase Document |
|
|
|
101.PRE (2) |
| XBRL Taxonomy Extension Presentation Linkbase Document |
(1)These exhibits were previously filed in the registrant’s Form 10-Q for the quarterly period ended December 31, 2020, filed with the Securities and Exchange Commission on December 31, 2020.
(2)Filed herewith
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Pharmagreen Biotech Inc. | |
|
| |
| By: | /s/ Peter Wojcik |
|
| Peter Wojcik |
|
| President and Director Principal Executive Officer |
|
| |
| By: | /s/ Terry Kwan |
|
| Terry Kwan |
|
| Principal Accounting Officer |
Dated February 23, 2021